TEAEs suspected by the investigator to be related to study drug, occurring in ≥2 patients, sorted by overall incidence.

aAll grade ≥3 TEAEs related to study drug were grade 3. Grade 3 events related to lenalidomide: fatigue (7; 2 events in 2 patients each), neutropenia (2), anorexia, hypokalemia, general physical health deterioration, diarrhea, increased gamma-glutamyltransferase, and decreased blood potassium. Grade 3 events related to cetuximab: rash (4; 3 events in 1 patient), fatigue (4; 2 events in 1 patient), hypersensitivity (3; 2 events in 1 patient), diarrhea (2), urticaria, general physical health deterioration, tachycardia, dyspnea, and hypertension.